What We're Reading: Page 123
Industry reads hand-picked by our editors
Mar 10, 2022
Mar 09, 2022
-
Fierce Pharma
Gilead Sciences will lay off 114 staffers based out of former Immunomedics headquarters
-
Endpoints News
ARCH and GV are building a large startup focused on mitochondrial diseases
-
Bloomberg
Pfizer to Submit Data to FDA on Fourth Covid Shot Soon, CEO Says
-
STAT
Gilead's Dan O'Day is charming — but charm hasn't staunched losses
Mar 08, 2022
-
STAT
Key Democrat moves to crack down on FDA accelerated approvals
-
Bloomberg
J&J's Controversial Prison Testing Resurfaces in Baby Powder Lawsuits
-
Endpoints News
An AI biotech emerges from stealth promising drugs 'on demand.' What will that look like, and is it even possible?
-
Evaluate Vantage
Novo makes a rare disease push
Mar 07, 2022
-
San Francisco Business Times
The next frontier of boardroom equity: science advisory boards
-
The New York Times
High Demand for Drug to Prevent Covid in the Vulnerable, Yet Doses Go Unused
-
The Financial Times
J&J targets Chinese biotech deals as western pharma groups look east
-
The Wall Street Journal
Novavax’s Covid-19 Vaccine Moves Closer to FDA Authorization Decision
Mar 04, 2022
-
STAT
Black biotech leaders struggle for funding amid industry diversity pledges
-
ProPublica
What’s Holding Up the COVID Vaccines for Children Under 5?
-
Science
After invasion, Ukrainian researchers turn into resistance fighters and refugees
-
The New York Times
Top U.S. health officials say they intend to offer other nations tech that might be used against Covid.
Mar 03, 2022
-
Business Insider
Biotech Startups Get Seed Funding From Tech Venture Capital Investors
-
Associated Press
Purdue Pharma, US states agree to new opioid settlement
-
The Washington Post
U.S. to share some coronavirus technologies with World Health Organization
Mar 02, 2022
-
The Washington Post
NIH orders sweeping review of potentially risky experiments on viruses and other pathogens
-
MIT Technology Review
The new malaria vaccine might not be perfect, but it will save countless lives
-
Bloomberg
Crispr Might Actually Live Up to Its Immense Hype
-
Fierce Biotech
Sanofi picks a 'safe' bet for Adagene's antibody tech in $2.5B biobucks tie up
Previous
